Laboratory Corporation of America this week commercially launched its MGMT methylation testing service to gauge patients’ responsiveness to cancer therapies.
For the test, LabCorp licensed OncoMethylome's MSP and MGMT DNA methylation marker technology.
OncoMethylome Sciences will receive royalty and milestone payments from LabCorp on the sales of the MGMT methylation testing service. Financial terms of the deal were not announced.
While its deal with LabCorp is for the North American market, OncoMethylome noted that efforts are underway to extend commercial availability of its technology to the European markets.